Role of cognitive testing in disease modifying ad trials

Journal of Nutrition, Health and Aging

Volumn 10, Issue 2, 2006, Pages 131-132

  Visser, P J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG SCREENING; FOLLOW UP; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 33645990264     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Christensen H, Hadzi-Pavlovic D, Jacomb P. The psychometric differentiation of dementia from normal aging: a meta-analysis. Psychological Assessment 1991;3:147-155.
2. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychol 2005;19:520-531.
3. Visser PJ, Verhey FRJ, Ponds RWHM, Jolles J. Diagnosis of preclinical Alzheimer's disease in a clinical setting. Int Psychogeriatr 2001;13:411-424.
4. Jack CR, Jr., Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60:253-260.
5. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. N Engl J Med 2005.
6. Barnes LL, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777-1781.